Drug intelligence / Profile preview

AZ58

Development stage: Preclinical
Modality: Small Molecules

Overview

AZ58 is a Smac mimetic that has been investigated for its potential to overcome chemotherapy resistance in urothelial cancer cells. It functions by inducing apoptosis, specifically by reducing the expression of inhibitor of apoptosis proteins (IAPs) such as cIAP1, cIAP2, and XIAP, and activating the NFκB pathway. Preclinical studies have shown that AZ58, particularly in combination with gemcitabine and cisplatin, can sensitize urothelial cancer cell lines to chemotherapy and decrease tumor burden in mouse models.

Targets

XIAP (Baculoviral IAP repeat-containing protein 4)BIRC3 (Baculoviral IAP repeat-containing protein 3)BIRC2 (Cellular inhibitor of apoptosis protein 1)

Beyond the preview

Go deeper on AZ58.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZ58.

Explore the full profile